[{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts","type":"changed","fields":[{"field":"summary","before":"\"MRD testing already detects relapse months before imaging, but sampling is episodic. Work on implantable and wearable sampling, microneedle interstitial-fluid collection, and at-home dried blood spots aims to shorten...","after":"\"MRD testing already detects relapse months before imaging, but sampling is episodic. Work on implantable and wearable sampling, microneedle interstitial-fluid collection, and at-home dried blood spots aims to shorten..."}]},{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","commit":"5c85c736e1","date":"2026-09-08","author":"Jude Gomila","message":"data(frontier): 45 radical frontier technologies and two horizon roadmaps","file":"src/data/frontier.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"sections"},{"field":"status"},{"field":"asOf"},{"field":"tldr"},{"field":"summary"},{"field":"principle"},{"field":"strengths"},{"field":"limitations"},{"field":"technologies"},{"field":"terms"},{"field":"companies"},{"field":"tags"},{"field":"links"}]}]